Archives: Speakers

Based in Stockholm, Joep Muselaers leads the Solutions Engineering teams for Cloudera across the Nordics and Benelux, focusing on the deployment of scalable data and AI strategies. With a tenured background at IBM and Sun Microsystems, he specializes in moving financial institutions from legacy infrastructure to hybrid-cloud architectures that support enterprise-grade machine learning. His current work centers on the industrialization of AI for high-stakes finance, specifically operationalizing fraud detection, anti-money laundering (AML), and regulatory compliance.

Stanko has over 20 years of experience in the resources industry. Working in roles spanning technology commercialisation, operations commissioning and financial implementation/investment. He leads a dynamic team focused on advancing projects and operations and driving innovation across the milling, flotation, leaching, smelting, refining and recycling value chain.

Biotech executive with 20+ years of experience driving innovation at the intersection of science, medicine, and technology. Currently VP, Head of Translational Medicine at Verge Genomics, where I built the function from the ground up and advanced neurology programs through Phase 2/3 readiness using FDA-validated biomarkers. Previously at Pfizer, I led cross-functional teams delivering novel digital endpoints, secured FDA/EMA alignment, and helped advance Ponsegromab from Phase 1 to Phase 2/3. At Biogen, I drove digital diagnostics initiatives, advanced technologies in Alzheimer’s and stroke, and helped spin out a new venture. I also founded a digital diagnostics startup, Usin’Life, which exited with a few assets. Passionate about advancing therapies for patients with high unmet medical needs, I bring expertise in translational medicine, biomarker strategy (digital & fluid), regulatory engagement, using technology ( including AI/ML !) and partnerships across biotech, pharma, and academia.

A highly accomplished physician, oncologist, pathologist, scientist, and senior medical leader with over 30 years of expertise in medicine and biopharmaceutical research and development, particularly in oncology. Renowned for proficiency in immuno-oncology, vaccine development, and fostering strategic collaborations across government, academia, hospitals, and industry. Demonstrates comprehensive expertise in clinical development, medical affairs, and navigating regulatory submissions (IND, BLA/NDA), with a proven record in leading and mentoring multidisciplinary teams. Skilled in building and guiding global oncology portfolios for diverse organizations, showcasing outstanding business acumen as a co-founder, board member, and a pivotal contributor to business development and alliance management. An extensive academic career includes mentoring, leading major clinical and research initiatives, and securing substantial research funding. Held key leadership roles such as Division Director, Department Head, and US Head of Global Oncology Development Unit. Committed to nurturing talent, team integration, and delivering impactful results, with exceptional communication skills that make complex scientific concepts accessible to diverse audiences. In addition to extensive scientific and medical accomplishments, am also a passionate advocate for human rights and social equity, recognizing socioeconomic inequalities as a profound threat to human well-being and a key driver of disease, necessitating decisive political action. Ran twice for President of the Democratic Republic of Congo, championing a platform focused on political and socioeconomic reforms, and advancing pro-poor policies.

Digital health product lead with expertise in SaMD, AI/ML-enabled screening, and clinical decision-support tools, with a track record of delivering multiple diagnostic devices that have achieved global regulatory clearance and market launch. My work spans diagnostics and digital health products across neurology, gastroenterology, oncology, and rare diseases.My role centers on building digital diagnostics platform capability—a reusable diagnostic foundation that supports therapeutic programs across the enterprise. This includes defining diagnostic value propositions, evidence requirements, technology development pathways, algorithm deployment frameworks, clinical workflow integration, and digital productization models that scale across the US, EU, Japan, and China.Backed by a strong foundation in regulated diagnostic development, I bring execution-focused leadership across the full product lifecycle—from requirements definition and validation planning to cross-functional alignment with clinical, translational science, regulatory, commercial, and global development partners.Previously a co-founder of a connected-health startup, I combine an innovation mindset with enterprise-level product leadership to shape Takeda’s approach to digital diagnostics, diagnostic algorithms, and clinical decision-support solutions.

Early Development Clinical Project and Team Leader, leading pre-clinical operational strategy and First In Human clinical trails globally.

I am a physician-scientist at the intersection of pathology diagnostics, AI, and drug development. Currently a Global Medical Affairs Lead in Pathology at Roche Diagnostics, my mission is to architect the next generation of precision diagnostics through the AI-enabled multimodal integration of digital pathology, spatial biology, and multianalyte tissue detection. With a career spanning elite research institutions and biopharma / diagnostics / biotech, I have a strong track record of bridging the gap between foundational biological discovery and the delivery of transformative clinical tools. Core Areas of Expertise: • Precision Diagnostics: Diagnostic and companion diagnostic (CDx) development, biomarker strategy, and technology assessment. • Digital & Spatial Innovation: AI-enabled integration of traditional morphology, molecular pathology, and spatial biology. • Clinical & Translational Leadership: USA board-certified anatomic pathologist with deep experience in drug safety (toxicology), translational medicine, molecular and investigative pathology, and medical affairs. • Strategic Diligence: Expert in biotech/biopharma life sciences and diagnostics diligence. My Journey: From Foundational Discoveries to Global Leadership From the beginning, my work has been rooted in a deep commitment to revealing and modeling human biology, which was first inspired by studying chemical engineering, cardiology, and immunology. During my MD-PhD at UCLA, I discovered the molecular basis of DNA-protein recognition by bHLH-PAS transcription factors—a finding that helped unify fields as diverse as cell fate determination, toxicology, circadian rhythms, and oxygen sensing. I further honed this expertise through a pathology residency and fellowships at Stanford University, where I later served as faculty. For nearly a decade, I balanced teaching and clinical practice with leading a research laboratory focused on genetics, developmental biology, and cancer biology at UT Southwestern. Since entering industry in 2009, I have applied this rigorous scientific lens to every stage of the drug and diagnostic lifecycle. My goal has been to evolve how we see and treat disease by merging traditional pathology with the power of modern digital and molecular tools.

Health and life sciences leader with extensive experience in patient advocacy and public policy.